The UK’s Vernalis has received a vital cash injection from equity fund Paul Capital Healthcare which will help the firm recover from the financial crisis caused by the rejection last year by US regulators of a supplementary filing for the migraine drug Frova.
Read MorePaul joins Internis from Sandoz, where he was Head of Biopharmaceuticals. Paul began his career with Galen 16 years ago, then moved to Shire Pharmaceuticals, where he successfully launched all the major specialist molecules for...
Read More
For investors the future is bright, but it isn’t pharma
Read More
Paul McGrade’s take on what the pharma industry should focus on now
Read More
